Supernus Pharmaceuticals (SUPN) Non-Current Assets (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Non-Current Assets of $704.6 million for Q2 2026, up 9.49% year-over-year from $643.5 million in Q2 2025, and down 8.39% on a QoQ basis from $769.1 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Non-Current Assets (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Non-Current Assets for 16 years, with the latest figure at $704.6 million in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $704.6 million, up 9.49% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.1 billion (up 15.63% YoY), and the FY2025 annual result was $808.5 million, up 18.54% from the prior year.
- Non-Current Assets fell to $704.6 million in Q2 2026, from $769.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.1 billion in Q1 2022 and troughed at $643.5 million in Q2 2025.
- A 5-year average of $823.2 million and a median of $796.5 million in 2023 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2023, when Non-Current Assets fell 18.98%; it then gained 18.54% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $968.4 million in 2022, then retreated by 18.98% to $784.6 million in 2023, then retreated by 13.07% to $682.0 million in 2024, then advanced by 18.54% to $808.5 million in 2025, then decreased by 12.85% to $704.6 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $704.6 million in Q2 2026, $769.1 million in Q1 2026, and $808.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | 704.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 704.61 Mn |
| Mar 31, 2026 | 769.15 Mn |
| Dec 31, 2025 | 808.47 Mn |
| Sep 30, 2025 | 825.86 Mn |
| Jun 30, 2025 | 643.54 Mn |
| Mar 31, 2025 | 659.71 Mn |
| Dec 31, 2024 | 682.00 Mn |
| Sep 30, 2024 | 702.70 Mn |
| Jun 30, 2024 | 724.83 Mn |
| Mar 31, 2024 | 759.77 Mn |
| Dec 31, 2023 | 784.56 Mn |
| Sep 30, 2023 | 835.80 Mn |
| Jun 30, 2023 | 869.56 Mn |
| Mar 31, 2023 | 908.47 Mn |
| Dec 31, 2022 | 968.36 Mn |
| Sep 30, 2022 | 1.03 Bn |
| Jun 30, 2022 | 1.07 Bn |
| Mar 31, 2022 | 1.07 Bn |
| Dec 31, 2021 | 1.09 Bn |
| Sep 30, 2021 | 886.67 Mn |